Jax DiEugenio

Dr Saeed on the Rationale for Evaluating the Combination of Zanzalintinib Plus Atezolizumab vs Regorafenib in mCRC

November 11th 2025

Anwar Saeed, MD, discusses the rationale behind the STELLAR-303 trial evaluating zanzalintinib plus atezolizumab vs regorafenib in pretreated mCRC

CONGRATS Trial Data of Nivolumab ± Relatlimab Highlight Clinical Value of Immunotherapy in TLS+ Soft Tissue Sarcoma

November 11th 2025

Nivolumab with or without relatlimab exceeded historical benchmarks in TLS-positive soft tissue sarcoma, validating TLS as a predictive biomarker.

FDA Approves OncoMate MSI Dx as Companion Diagnostic for Pembrolizumab/Lenvatinib in MSS Endometrial Cancer

November 11th 2025

OncoMate MSI Dx was approved by the FDA to identify patients with MSS endometrial cancer who may be eligible for pembrolizumab plus lenvatinib.

Detalimogene Produces 63% CR Rate in BCG-Unresponsive NMIBC with CIS

November 11th 2025

Findings from the preliminary cohort show 3- and 6-month CR rates of 56% and 62%, respectively, with detalimogene in this patient population.

Precision Survivorship Platforms Are Essential for Improved, Equitable Care in Pediatric and AYA Sarcoma

November 11th 2025

R. Lor Randall, MD, FACS, advocates for precision-based survivorship models in pediatric/AYA sarcoma to address disparities and improve long-term outcomes.

At 3 Years, Eque-Cel Displays Deep and Durable Responses in Relapsed Multiple Myeloma

November 11th 2025

Long-term data reveal deep remissions with eque-cel, suggesting durable disease control with BCMA-directed CAR T-cell therapy in relapsed multiple myeloma.

Zanzalintinib Plus Atezolizumab Signals New Progress for Previously Treated mCRC

November 10th 2025

Anwar Saeed, MD, discusses findings of zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer.

Darovasertib Plus Crizotinib Could Represent Systemic Therapy Intended for Broader Metastatic Uveal Melanoma Population

November 7th 2025

Marlana Orloff, MD, discusses data for the combination of darovasertib and crizotinib in metastatic uveal melanoma.

BVd Approval Reframes Considerations Around Sequencing BCMA-Targeted Therapies in R/R Myeloma

November 7th 2025

Surbhi Sidana, MD, and Joshua Richter, MD, discuss the FDA approval of BVd for relapsed/refractory myeloma after at least 2 prior lines of therapy.

Dr Wang on the Safety Profile of CNS Bridging Radiotherapy Prior to CAR T in B-Cell Lymphoma

November 6th 2025

Pule Wang, MD, discusses safety data with CNS bridging radiotherapy before CAR T in B-cell lymphoma.

Dr Tagawa on the Efficacy of Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI and ADT in PSMA+ mHSPC

November 6th 2025

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the efficacy of lutetium Lu 177 vipivotide tetraxetan plus ARPI and ADT in mHSPC.

Dynamic Frailty Assessment Underscores Need for Ongoing Evaluation in Transplant-Ineligible Multiple Myeloma: With Hira Mian, MD, MSc, FRCPC

November 6th 2025

Hira Mian, MD, MSc, discusses why frailty should be understood as a dynamic, evolving clinical state rather than a fixed baseline characteristic for patients with multiple myeloma.

Dr Mayer on PRO Data With Camizestrant Plus CDK4/6 Inhibition in ESR1+ Breast Cancer

November 5th 2025

Erica L. Mayer, MD, MPH, discussed PRO data in ESR1 mutation–emergent breast cancer following switch therapy to camizestrant plus a CDK4/6 inhibitor.

Dr Tarantino on the Efficacy of Neoadjuvant T-DXd/THP in High-Risk HER2+ Breast Cancer

November 5th 2025

Paolo Tarantino, MD, PhD, discussed the clinical implications of the DESTINY-Breast11 trial of T-DXd/THP in high-risk, HER2-positive early breast cancer.

Dr Tolaney on the Efficacy of T-DXd in HER2+ Breast Cancer in the Post-Neoadjuvant Setting

November 5th 2025

Sara M. Tolaney, MD, MPH, discussed the use of T-DXd in patients with HER2-positive breast cancer with residual disease after neoadjuvant therapy.

Dr Dent on the Potential Role of Dato-DXd for Immunotherapy-Ineligible TNBC

November 5th 2025

Rebecca Dent, MD, MSc, FRCP, discussed the future implications of data with first-line Dato-DXd in locally recurrent inoperable or metastatic TNBC.

Dr Kalinsky on the Importance of Novel Second-Line Therapies for HR+ Breast Cancer

November 5th 2025

Kevin Kalinsky, MD, MS, FASCO, discusses research needs to improve treatment strategies in the post-CDK4/6 inhibitor setting for HR-positive breast cancer.

Dr Haake on the Rationale for a Tumor Subtype Analysis of Cabozantinib Plus Nivolumab in Metastatic ccRCC

November 5th 2025

JAK Inhibitor Selection and Sequencing Strategies Are Key in Myelofibrosis Management

November 5th 2025

Akriti Jain, MD, discusses treatment selection and sequencing of JAK inhibitors in myelofibrosis, emerging CALR-targeted research, and defining disease modification.

FDA Grants Orphan Drug Designation to M2T-CD33 for Acute Myeloid Leukemia

November 5th 2025

The FDA has granted orphan drug designation to M2T-CD33 for the treatment of patients with acute myeloid leukemia.